Antonio Almeida is currently head of department at Hospital da Luz, Lisbon, Portugal and also head of the hemato-oncology diagnostic laboratory at the Portuguese Institute of Oncology in Lisbon.
He was awarded his medical degree in 1993 from Cambridge University, UK, and completed his Specialist Training in Haematology in the UK in 2002. Following this Dr Almeida completed a clinical research fellowship through the Leukaemia Research Fund at Imperial College, London, and was awarded a PhD in 2007 for his work on the molecular characterization and targeted therapy for Inherited GPI Deficiency.
Dr Almeida’s research interests include myeloproliferative and myelodysplastic syndromes, focusing on epigenetic regulation of transcription regulation. He leads a Haematology Epigenetic research group and is the national principal investigator for several clinical trials in CML and MDS.
Dr Almeida has written book chapters and is the author of a range of articles published in journals including New England Journal of Medicine, Nature Medicine and Blood.